secwatch / observer
CRBU Caribou Biosciences, Inc.
CIK 0001619856 50 ready 8-Ks latest October 6, 2026, 4:07 PM ET RSS · JSON
Activity: NORMAL 1 filings / 30d vs 1 baseline
Ready 8-Ks 50
Latest filing October 6, 2026, 4:07 PM ET
Top materiality 0.85
Event mix other_material ×21 · earnings ×14 · regulatory ×6
Sentiment 22 pos · 6 neg · 22 neu
Latest earnings reported 2026-Q1
Executive change recent →
SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for CRBU

Highest-materiality recent filing

Caribou Biosciences halts vispa-cel and CB-011 CAR-T programs, cuts workforce, explores strategic alternatives

October 6, 2026, 4:07 PM ET other material materiality 0.85 negative item 2.05item 5.02item 7.01item 8.01item 9.01 ◈ executive_change

Read filing →

Executive changes

Departed

Sriram Ryali

Chief Financial Officer
CRBU · Caribou Biosciences, Inc.
Filed
October 6, 2026, 4:07 PM ET
The employment of Sriram Ryali, the Company’s Chief Financial Officer, will terminate on the date the Company executes a binding definitive agreement for a strategic alternative, and such termination would be treated as a termination “without cause” under the Employment Agreement, dated January 2, 2025, between the Company and Mr. Ryali (the “Ryali Employment Agreement”).
Appointed

Sriram Ryali

Chief Financial Officer
CRBU · Caribou Biosciences, Inc.
Effective
2025-01-02
Filed
January 2, 2025, 6:59 PM ET
On January 2, 2025, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), announced the appointment of Sriram Ryali, age 44, to the position of Chief Financial Officer (“CFO”) of the Company, effective as of January 2, 2025 (the “Start Date”).
Appointed (interim)

Ryan Fischesser

Interim Principal Financial Officer and Interim Principal Accounting Officer
CRBU · Caribou Biosciences, Inc.
Effective
2024-09-27
Filed
September 27, 2024, 7:59 PM ET
On September 23, 2024, Caribou Biosciences, Inc. (the “Company”) designated Ryan Fischesser, the Company’s current Vice President of Finance and Controller, as the Company’s interim principal financial officer and interim principal accounting officer, effective as of 5:00 p.m. Pacific time on September 27, 2024.
Departed

Jason O'Byrne

Chief Financial Officer
CRBU · Caribou Biosciences, Inc.
Effective
2024-09-27
Filed
September 27, 2024, 7:59 PM ET
Mr. O’Byrne serves as the Company’s principal financial officer and principal accounting officer through September 27, 2024, his final day with the Company.
Departed

Jason O'Byrne

Chief Financial Officer
CRBU · Caribou Biosciences, Inc.
Effective
2024-09-27
Filed
September 3, 2024, 7:59 PM ET
On September 1, 2024, Jason O’Byrne, the Chief Financial Officer of Caribou Biosciences, Inc. (the “Company”), informed the Company of his intent to resign from his position, effective September 27, 2024, to pursue another opportunity.
Appointed

Ryan Fischesser

principal accounting officer
CRBU · Caribou Biosciences, Inc.
Effective
2024-09-27
Filed
September 3, 2024, 7:59 PM ET
The Company intends to appoint Ryan Fischesser, the Company’s current Vice President of Finance and Controller, to assume the role of the Company’s principal accounting officer, effective as of the close of business on September 27, 2024.
Departed

Syed Rizvi

Chief Medical Officer
CRBU · Caribou Biosciences, Inc.
Effective
2023-12-31
Filed
December 22, 2023, 6:59 PM ET
As previously announced on December 12, 2023, Syed Rizvi, M.D., the Chief Medical Officer of Caribou Biosciences, Inc. (the “Company”), will be leaving the Company effective December 31, 2023.
Departed

Syed Rizvi

Chief Medical Officer
CRBU · Caribou Biosciences, Inc.
Effective
2023-12-31
Filed
December 12, 2023, 6:59 PM ET
Syed Rizvi, M.D., the Chief Medical Officer of Caribou Biosciences, Inc. (the “Company”), will be leaving the Company effective December 31, 2023.
Role change

Ryan Fischesser

principal accounting officer
CRBU · Caribou Biosciences, Inc.
Effective
2022-12-15
Successor
Jason V. O'Byrne
Filed
December 16, 2022, 6:59 PM ET
The Company’s Vice President of Finance and Controller, Ryan Fischesser, who was previously serving as the Company’s principal accounting officer, will continue serving as the Company’s Vice President of Finance and Controller but not as the Company’s principal accounting officer, effective as of December 15, 2022.
Role change

Jason V. O'Byrne

principal accounting officer
CRBU · Caribou Biosciences, Inc.
Effective
2022-12-15
Filed
December 16, 2022, 6:59 PM ET
On December 15, 2022, Caribou Biosciences, Inc. (the “Company”) appointed Jason V. O’Byrne, its Chief Financial Officer, as the Company’s principal accounting officer.
Appointed

David L. Johnson

Class II director
CRBU · Caribou Biosciences, Inc.
Effective
2022-05-11
Filed
May 11, 2022, 7:59 PM ET
increased the size of the Board from seven to eight directors and unanimously agreed to extend an offer to David L. Johnson, M.B.A., to serve as a Class II director of the Company.
Appointed

Dara Richardson-Heron

Class III Director
CRBU · Caribou Biosciences, Inc.
Effective
2021-11-04
Filed
November 8, 2021, 6:59 PM ET
On November 4, 2021, the Board of Directors (the “Board”) of Caribou Biosciences, Inc., a Delaware corporation (the “Company”), increased the size of the Board from six to seven directors and unanimously agreed to extend an offer to Dara Richardson-Heron, M.D., to serve as a Class III director of the Company.

Earnings & guidance

2026-Q1 EPS reported -$0.26 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event other_material

22 positive 6 negative 22 neutral

source · CRBU on sec.gov